β1-Adrenoceptor blocker aggravated ventricular arrhythmia

Pacing Clin Electrophysiol. 2013 Nov;36(11):1348-56. doi: 10.1111/pace.12196. Epub 2013 Jun 10.

Abstract

Objectives: To assess the impact of β1 -adrenoceptor blockers (β1 -blocker) and isoprenaline on the incidence of idiopathic repetitive ventricular arrhythmia that apparently decreases with preprocedural anxiety.

Methods: From January 2010 to July 2012, six patients were identified who had idiopathic ventricular arrhythmias that apparently decreased (by greater than 90%) with preprocedural anxiety. The number of ectopic ventricular beats per hour (VPH) was calculated from Holter or telemetry monitoring to assess the ectopic burden. The mean VPH of 24 hours from Holter before admission (VPH-m) was used as baseline (100%) for normalization. β1 -Blockers, isoprenaline, and/or aminophylline were administrated successively on the ward and catheter lab to evaluate their effects on the ventricular arrhythmias.

Results: Among 97 consecutive patients with idiopathic ventricular arrhythmias, six had reduction in normalized VPHs in the hour before the scheduled procedure time from (104.6 ± 4.6%) to (2.8 ± 1.6%) possibly due to preprocedural anxiety (P < 0.05), then increased to (97.9 ± 9.7%) during β1 -blocker administration (P < 0.05), then quickly reduced to (1.6 ± 1.0%) during subsequent isoprenaline infusion. Repeated β1 -blocker quickly counteracted the inhibitory effect of isoprenaline, and VPHs increased to (120.9 ± 2.4%) from (1.6 ± 1.0%; P < 0.05). Isoprenaline and β1 -blocker showed similar effects on the arrhythmias in catheter lab.

Conclusions: In some patients with structurally normal heart and ventricular arrhythmias there is a marked reduction of arrhythmias associated with preprocedural anxiety. These patients exhibit a reproducible sequence of β1 -blocker aggravation and catecholamine inhibition of ventricular arrhythmias, including both repetitive ventricular premature beats and monomorphic ventricular tachycardia.

Keywords: isoprenaline; monomorphic ventricular tachycardia; ventricular premature beat; β1-adrenoceptor blocker.

Publication types

  • Case Reports
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adrenergic beta-1 Receptor Antagonists / adverse effects*
  • Adrenergic beta-1 Receptor Antagonists / therapeutic use*
  • Adrenergic beta-Agonists / adverse effects
  • Adrenergic beta-Agonists / therapeutic use
  • Adult
  • Aminophylline / adverse effects
  • Aminophylline / therapeutic use
  • Female
  • Humans
  • Isoproterenol / adverse effects
  • Isoproterenol / therapeutic use
  • Male
  • Middle Aged
  • Purinergic P1 Receptor Antagonists / adverse effects
  • Purinergic P1 Receptor Antagonists / therapeutic use
  • Tachycardia, Ventricular / chemically induced*
  • Tachycardia, Ventricular / diagnosis
  • Tachycardia, Ventricular / prevention & control*
  • Treatment Outcome
  • Ventricular Premature Complexes / chemically induced*
  • Ventricular Premature Complexes / diagnosis
  • Ventricular Premature Complexes / prevention & control*

Substances

  • Adrenergic beta-1 Receptor Antagonists
  • Adrenergic beta-Agonists
  • Purinergic P1 Receptor Antagonists
  • Aminophylline
  • Isoproterenol